LinkedIn Profile

Access Atlantic Healthcare historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:atlantichc 553433 Nov 18th, 2019 12:00AM Atlantic Healthcare plc 831 18.00 Open Pharmaceuticals Nov 18th, 2019 03:46PM Nov 18th, 2019 03:46PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 16th, 2019 12:00AM Atlantic Healthcare plc 831 18.00 Open Pharmaceuticals Nov 16th, 2019 03:57PM Nov 16th, 2019 03:57PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 15th, 2019 12:00AM Atlantic Healthcare plc 831 18.00 Open Pharmaceuticals Nov 15th, 2019 12:39PM Nov 15th, 2019 12:39PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 14th, 2019 12:00AM Atlantic Healthcare plc 831 18.00 Open Pharmaceuticals Nov 14th, 2019 05:55PM Nov 14th, 2019 05:55PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 13th, 2019 12:00AM Atlantic Healthcare plc 829 18.00 Open Pharmaceuticals Nov 13th, 2019 01:07PM Nov 13th, 2019 01:07PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 12th, 2019 12:00AM Atlantic Healthcare plc 829 18.00 Open Pharmaceuticals Nov 12th, 2019 02:49PM Nov 12th, 2019 02:49PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 11th, 2019 12:00AM Atlantic Healthcare plc 829 18.00 Open Pharmaceuticals Nov 11th, 2019 02:47PM Nov 11th, 2019 02:47PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 10th, 2019 12:00AM Atlantic Healthcare plc 829 18.00 Open Pharmaceuticals Nov 10th, 2019 05:54PM Nov 10th, 2019 05:54PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 9th, 2019 12:00AM Atlantic Healthcare plc 828 18.00 Open Pharmaceuticals Nov 9th, 2019 05:21PM Nov 9th, 2019 05:21PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH
private:atlantichc 553433 Nov 8th, 2019 12:00AM Atlantic Healthcare plc 828 18.00 Open Pharmaceuticals Nov 8th, 2019 02:31PM Nov 8th, 2019 02:31PM Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases. Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD. ​ We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options. Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications. Open High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis Open Atlantic House, 12 Rose and Crown Walk Saffron Walden Essex GB CB10 1JH

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.